Bristol-Myers Squibb (BMY) News and press releases

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says

20 Mar 23

Analyst Color, Biotech, Large Cap, News, Health Care, Analyst Ratings, General

CHARM Therapeutics Announced A Strategic Discovery Collaboration With Bristol Myers Squibb To Identify And Optimize Compounds Against Bristol Myers' Selected Targets, CHARM Will Leverage DragonFold Platform, Deal Terms Were Not Disclosed

20 Mar 23

Biotech, Large Cap, News, Health Care, Contracts, General

Under the terms of the agreement, CHARM is responsible for the early discovery of compounds against targets of interest to Bristol Myers Squibb, who has the option to license and develop compounds from the collaboration.

Evotec Announced Progress Within Its Partnership With Bristol Myers Squibb Relating To Building A Molecular Glue-based Pipeline. Performance And Program-based Achievements Trigger $75M To Evotec

16 Mar 23

Biotech, News, Health Care, Contracts, General

Evotec and Bristol Myers Squibb entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the highly productive initial collaboration generating a promising

Exscientia Announced Two New Wholly-owned Precision Oncology Development Candidates, EXS74539, And EXS73565. IND-enabling Studies Are Underway And The Company Expects To Provide An Update On Clinical Development Plans In 2H Of 2023

14 Mar 23

Biotech, News, Health Care, General

Both molecules were funded through a 2019 collaboration with Celgene, which was acquired by Bristol Myers Squibb, and each molecule met the criteria for which BMS could exercise its option. Bristol Myers Squibb's

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation

13 Mar 23

Biotech, Government, Large Cap, News, Regulations, Health Care, General

How Is The Market Feeling About Bristol-Myers Squibb?

9 Mar 23

Short Sellers, Short Ideas, Trading Ideas

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason

7 Mar 23

Biotech, News, Penny Stocks, Sector ETFs, Health Care, Small Cap, Movers, ETFs, General

Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023

6 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Where Bristol-Myers Squibb Stands With Analysts

6 Mar 23

Analyst Ratings

Jefferies Initiates Coverage On Bristol-Myers Squibb with Hold Rating, Announces Price Target of $62

6 Mar 23

News, Price Target, Initiation, Analyst Ratings

Jefferies analyst Akash Tewari initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Hold rating and announces Price Target of $62.

Viz.ai Announces Agreement With Bristol Myers Squibb To Enable Earlier Detection And Management Of Suspected Hypertrophic Cardiomyopathy

3 Mar 23

Biotech, News, General

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM Viz.ai, a leader in AI-powered disease detection and care

The European Commission Has Approved Bristol Myers Squibb's Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia

3 Mar 23

Biotech, Large Cap, News, Health Care, General

The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were

Why Nektar Therapeutics Stock Is Plunging Today

24 Feb 23

Biotech, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, Movers, General

Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years

17 Feb 23

Biotech, Large Cap, News, Health Care, General

Bristol Myers Squibb Announces Adjuvant Opdivo Continues To Provide Significant, Durable Clinical Benefits For Patients With Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years In CheckMate -274 Trial

17 Feb 23

Biotech, News, FDA, General

Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with

Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer

14 Feb 23

Biotech, Large Cap, News, Health Care, General

Opdivo In Combination With CABOMETYX Shows Durable Survival With Over Three Years Of Follow-Up In The CheckMate -9ER Trial In First-Line Advanced Renal Cell Carcinoma

14 Feb 23

Biotech, News, FDA, General

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to

A Bearish Sign Appears On Bristol-Myers Squibb's Chart

13 Feb 23

Markets, Movers, Trading Ideas

Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients

10 Feb 23

Biotech, Large Cap, News, Health Care, Small Cap, General

Bristol-Myers Squibb Highlights Abecma Data; Says Reduced Risk Of Disease Progression Or Death By 51% Vs Standard Regimens In Earlier Lines Of Therapy

10 Feb 23

News, FDA

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?

22 Mar 23

Melville, NY--News Direct--By Julian Richard, Benzinga

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

20 Mar 23

Press Releases

Collaboration will leverage CHARM's DragonFold deep learning platform to identify compounds against targets of interest CHARM Therapeutics ("CHARM"), a 3D deep learning biotechnology company discovering and developing

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

15 Mar 23

Press Releases

- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities - $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing

Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023

9 Mar 23

Press Releases

Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2023 on Thursday, April 27, 2023. Company executives will review financial results and address inquiries from investors and analysts during

Bristol Myers Squibb Announces Dividend

3 Mar 23

Press Releases

Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is

Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

3 Mar 23

Press Releases

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM Viz.ai, a leader in AI-powered disease detection and care

Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

3 Mar 23

Press Releases

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has granted

The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor

2 Mar 23

Press Releases

The Librexia program is the most comprehensive Factor XIa Phase 3 clinical development program, and will provide indispensable data from nearly 50,000 patients across three simultaneous trials including Librexia STROKE,

Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care Conference

28 Feb 23

Press Releases

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Samit Hirawat, M.D., Executive Vice President,

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….

28 Feb 23

Press Releases

The applications are based on results from the Phase 3 CheckMate -76K trial, in which Opdivo demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival The U.S. Food and Drug

Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology

27 Feb 23

Press Releases

Data across EXPLORER-HCM, MAVA-LTE and PIONEER-OLE add to the growing body of evidence from the CAMZYOS® (mavacamten) development program, reinforcing the therapeutic value and benefit to patients Bristol Myers

Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029

22 Feb 23

Small Cap, Opinion, Press Releases

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Feb. 22, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of

Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial

17 Feb 23

Press Releases

Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with

Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms

16 Feb 23

Press Releases

Approximately 9.5 million people in the U.S. are projected to have AFib in 2023, with the number expected to rise to approximately 12.1 million by 2030; many ignore their symptoms, not realizing that AFib increases

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

13 Feb 23

Press Releases

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to sunitinib, regardless of

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

10 Feb 23

Press Releases

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

3 Feb 23

Press Releases

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023. Chris Boerner, Ph.D.,

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

2 Feb 23

Press Releases

Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia

27 Jan 23

Press Releases

Approval by the European Commission would expand the indications of Reblozyl for treatment of anemia in adults with beta thalassemia in Europe In the pivotal BEYOND study, Reblozyl significantly increased hemoglobin

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

27 Jan 23

Press Releases

CHMP recommendation based on positive results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial Sotyktu has demonstrated superior